#news #biotech Chutes & Ladders—Curis moves up COO as CEO Fattaey departs

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Chutes & Ladders—Curis moves up COO as CEO Fattaey departs .Curis moves up COO as CEO Fattaey leaves company; Merck’s board scraps mandatory retirement to keep CEO Ken Frazier; and Bayer’s Americas pharma head takes CEO job at Selecta Biosciences. Those moves plus more hirings, firings and retirings throughout the industry.

from FierceBiotech: Biotech https://ift.tt/2IodDoz

#news #biotech Hitchhikers hinder medication shelf life

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Hitchhikers hinder medication shelf life .Why some biopharmaceuticals have a longer shelf life than others is a problem that has baffled scientists and manufacturers alike. Even the same medication, produced by different manufacturers, can vary in its storage life.

from Biotechnology News – Biology News https://ift.tt/2OeoIOr

#news #biotech U.K. VC funding hits new high after bumper quarter

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: U.K. VC funding hits new high after bumper quarter .The British biotech sector enjoyed a big third quarter for VC financing. With more than £460 million ($600 million) in VC cash flowing into the bank accounts of U.K. biotechs, the sector has now raised 30% more money from public and private sources than it managed in all of last year. 

from FierceBiotech: Biotech https://ift.tt/2OfOl1n

#news #biotech Johnson & Johnson CAR-T partner GenScript yo-yos on fake data allegations

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Johnson & Johnson CAR-T partner GenScript yo-yos on fake data allegations .Hong Kong biotech GenScript has had a turbulent 48 hours, with its shares plummeting yesterday on allegations of data falsification in a CAR-T program, only to rebound after it strongly denied the claims.

from FierceBiotech: Biotech https://ift.tt/2zCegrC

#news #biotech Roche pays €70M upfront for Tusk’s preclinical Treg depleter

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Roche pays €70M upfront for Tusk’s preclinical Treg depleter .Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests.

from FierceBiotech: Biotech https://ift.tt/2Qgf773

#news #biotech Aphids use sight to avoid deadly bacteria, could lead to pest control

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Aphids use sight to avoid deadly bacteria, could lead to pest control .Pea aphids—a serious agricultural pest—have the ability to see and avoid a common, aphid-killing bacteria on plant leaves, according to a new Cornell University study published in Current Biology.

from Biotechnology News – Biology News https://ift.tt/2NKP6jf

#news #biotech Eli Lilly nets an early-stage GLP-1 diabetes drug from Chugai for $50M

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Eli Lilly nets an early-stage GLP-1 diabetes drug from Chugai for $50M .Eli Lilly & Co. is looking to pad out its diabetes portfolio by licensing an oral, nonpeptidic GLP-1 receptor agonist from Chugai Pharmaceutical that the company describes as a “phase 1 ready” asset for the treatment of Type 2 disease.

from FierceBiotech: Biotech https://ift.tt/2NP46wV

#news #biotech Novel Approach Brings Personalized Melanoma Treatment Closer to Reality

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Novel Approach Brings Personalized Melanoma Treatment Closer to Reality .A team of melanoma researchers used a novel “HLA peptidomics” method to identify and isolate cancer-specific neo-antigens, which could be…

from Therapeutics | Bio Research International https://ift.tt/2zAjhkM

#news #biotech Bayer’s Americas pharma head takes CEO job at Selecta Biosciences

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bayer’s Americas pharma head takes CEO job at Selecta Biosciences .Bayer’s Carsten Brunn, Ph.D., has been named president and CEO of Selecta Biosciences. He will take over following the retirement of Werner Cautreels, Ph.D., effective Dec. 1.

from FierceBiotech: Biotech https://ift.tt/2zAkZCz